No psychedelic NDA will receive FDA approval in 2026; any reviewed application will face demands for confirmatory durability data and functional-unblinding mitigation.

The FDA will not fully approve any psychedelic-based medicine this year. The main reason: drug companies haven't solved two big problems — first, their studies are hard to run fairly because people almost always know whether they got the real drug (you can tell when you're tripping), and second, we don't yet know how long the benefits last. The FDA won't approve something when those gaps exist, because its job is to protect patients from treatments that might not work as advertised.

Functional unblinding remains the unresolved methodological weakness across the field, and durability evidence is thin. FDA's patient-protection mandate makes approval without addressing these issues highly unlikely within the year.